Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)
Agency
National Institutes of Health
Posted
Sep 1, 2026
Due Date
Oct 9, 2028
Description
The purpose of this notice of funding opportunity (NOFO) is to support research that advances understanding of the natural history of radiation or chemical exposures; develops relevant injury models; identifies and validates diagnostic tools, biomarkers, or triage technologies; and supports the development of effective medical countermeasures (MCMs) to mitigate or treat acute and/or delayed injuries resulting from radiological/nuclear or chemical public health emergencies.
AI Summary
Agency: National Institutes of Health
Details
- Notice ID
- 361833
- Solicitation Number
- RFA-AI-27-014
- Classification Code
- D
Want to track opportunities like this?
Sign up for Kontratar to get AI-powered opportunity matching, ranking, and alerts.
Get Started FreeRelated opportunities
- Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)
National Institutes of Health
- Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
National Institutes of Health
- Research on System Support and Tools for Provider Training and Quality Monitoring for Suicide Preventive Care (RP1- Clinical Trial Optional)
National Institutes of Health
- Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Research Centers (U01 Clinical Trial Not Allowed)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) Scientific Data Research Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
National Institutes of Health